PDCD1 and non-small cell lung carcinoma: During the last years, immunotherapy with immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) has revolutionized the treatment of advanced NSCLC [3,4].